Artios Pharma

Cambridge, United Kingdom

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

$115.0M raised

Nov 2025

Series D

Biopharma Biotechnology Medical Device

Top Investors

RA Capital ManagementSchroders CapitalSofinnova PartnersAbbVieEQT Life Sciences

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Artios Pharma

How much funding has Artios Pharma raised?

Artios Pharma has raised $115.0M in total funding. The most recent round was Series D. The last funding was announced in November 2025.

Who are Artios Pharma's investors?

Artios Pharma's investors include RA Capital Management, Schroders Capital, Sofinnova Partners, AbbVie, EQT Life Sciences.

Where is Artios Pharma headquartered?

Artios Pharma is headquartered in Cambridge, United Kingdom.

What does Artios Pharma do?

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

What stage is Artios Pharma at?

Artios Pharma is at the Series D stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated November 17, 2025.

MLA

"Artios Pharma — Funding & Investors." VCBacked, November 17, 2025, https://www.vcbacked.co/company/artios-pharma. Accessed June 4, 2026.

APA

VCBacked. (2025). Artios Pharma — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/artios-pharma

Wikipedia (cite web)

{{cite web |title=Artios Pharma — Funding & Investors |url=https://www.vcbacked.co/company/artios-pharma |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated November 17, 2025.

Similar Companies in Biopharma